Literature DB >> 22820394

Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity.

Aaron B Krueger1, Seameen J Dehdashti2, Noel Southall2, Juan J Marugan2, Marc Ferrer2, Xueni Li1, Heide L Ford1,3,4, Wei Zheng2, Rui Zhao1.   

Abstract

Eya proteins are essential coactivators of the Six family of homeobox transcription factors and also contain a unique protein tyrosine phosphatase activity, belonging to the haloacid dehalogenase family of phosphatases. The phosphatase activity of Eya is important for a subset of Six1-mediated transcription, making this a unique type of transcriptional control. It is also responsible for directing cells to the repair instead of apoptosis pathway upon DNA damage. Furthermore, the phosphatase activity of Eya is critical for transformation, migration, invasion, and metastasis of breast cancer cells. Thus, inhibitors of the Eya phosphatase activity may be antitumorigenic and antimetastatic, as well as sensitize cancer cells to DNA damage-inducing therapies. In this article, we identified a previously unknown chemical series using high-throughput screening that inhibits the Eya2 phosphatase activity with IC(50)s ranging from 1.8 to 79 µM. Compound activity was confirmed using an alternative malachite green assay and H2AX, a known Eya substrate. Importantly, these Eya2 phosphatase inhibitors show specificity and do not significantly inhibit several other cellular phosphatases. Our studies identify the first selective Eya2 phosphatase inhibitors that can potentially be developed into chemical probes for functional studies of Eya phosphatase or into anticancer drugs in the future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820394      PMCID: PMC3893891          DOI: 10.1177/1087057112453936

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  29 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  Protein tyrosine phosphatases: from genes, to function, to disease.

Authors:  Nicholas K Tonks
Journal:  Nat Rev Mol Cell Biol       Date:  2006-11       Impact factor: 94.444

3.  Regulation of the innate immune response by threonine-phosphatase of Eyes absent.

Authors:  Yasutaka Okabe; Teruyuki Sano; Shigekazu Nagata
Journal:  Nature       Date:  2009-06-28       Impact factor: 49.962

Review 4.  The phosphoprotein phosphatase family of Ser/Thr phosphatases as principal targets of naturally occurring toxins.

Authors:  Susana R Pereira; Vítor M Vasconcelos; Agostinho Antunes
Journal:  Crit Rev Toxicol       Date:  2011-02       Impact factor: 5.635

5.  Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival.

Authors:  Kian Behbakht; Lubna Qamar; Carrie S Aldridge; Ricardo D Coletta; Susan A Davidson; Andrew Thorburn; Heide L Ford
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

6.  Biochemical characterization and deletion analysis of recombinant human protein phosphatase 2C alpha.

Authors:  A E Marley; J E Sullivan; D Carling; W M Abbott; G J Smith; I W Taylor; F Carey; R K Beri
Journal:  Biochem J       Date:  1996-12-15       Impact factor: 3.857

7.  A comparative study of Eya1 and Eya4 protein function and its implication in branchio-oto-renal syndrome and DFNA10.

Authors:  Yuzhou Zhang; Boyd M Knosp; Mark Maconochie; Rick A Friedman; Richard J H Smith
Journal:  J Assoc Res Otolaryngol       Date:  2004-06-24

8.  Suppression of tumorigenesis and metastasis of hepatocellular carcinoma by shRNA interference targeting on homeoprotein Six1.

Authors:  Kevin T P Ng; Terence K W Lee; Qiao Cheng; Jana Y H Wo; Chris K W Sun; Dong-Yong Guo; Zophia X Lim; Chung-Mau Lo; Ronnie T P Poon; Sheung-Tat Fan; Kwan Man
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

9.  Dephosphorylation of the C-terminal tyrosyl residue of the DNA damage-related histone H2A.X is mediated by the protein phosphatase eyes absent.

Authors:  Navasona Krishnan; Dae Gwin Jeong; Suk-Kyeong Jung; Seong Eon Ryu; Andrew Xiao; C David Allis; Seung Jun Kim; Nicholas K Tonks
Journal:  J Biol Chem       Date:  2009-04-07       Impact factor: 5.157

10.  Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties.

Authors:  S M Farabaugh; D S Micalizzi; P Jedlicka; R Zhao; H L Ford
Journal:  Oncogene       Date:  2011-06-27       Impact factor: 9.867

View more
  14 in total

1.  A potent and selective inhibitor for the UBLCP1 proteasome phosphatase.

Authors:  Yantao He; Xing Guo; Zhi-Hong Yu; Li Wu; Andrea M Gunawan; Yan Zhang; Jack E Dixon; Zhong-Yin Zhang
Journal:  Bioorg Med Chem       Date:  2015-03-31       Impact factor: 3.641

2.  Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration.

Authors:  Aaron B Krueger; David J Drasin; Wendy A Lea; Aaron N Patrick; Samarjit Patnaik; Donald S Backos; Christopher J Matheson; Xin Hu; Elena Barnaeva; Michael J Holliday; Melanie A Blevins; Tyler P Robin; Elan Z Eisenmesser; Marc Ferrer; Anton Simeonov; Noel Southall; Philip Reigan; Juan Marugan; Heide L Ford; Rui Zhao
Journal:  J Biol Chem       Date:  2014-04-22       Impact factor: 5.157

Review 3.  The multi-functional eyes absent proteins.

Authors:  Rashmi S Hegde; Kaushik Roychoudhury; Ram Naresh Pandey
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-07-29       Impact factor: 8.250

Review 4.  The SIX1-EYA transcriptional complex as a therapeutic target in cancer.

Authors:  Melanie A Blevins; Christina G Towers; Aaron N Patrick; Rui Zhao; Heide L Ford
Journal:  Expert Opin Ther Targets       Date:  2015-01-02       Impact factor: 6.902

5.  Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.

Authors:  Rebecca L Vartuli; Hengbo Zhou; Lingdi Zhang; Rani K Powers; Jared Klarquist; Pratyaydipta Rudra; Melanie Y Vincent; Debashis Ghosh; James C Costello; Ross M Kedl; Jill E Slansky; Rui Zhao; Heide L Ford
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

6.  A phosphotyrosine switch determines the antitumor activity of ERβ.

Authors:  Bin Yuan; Long Cheng; Huai-Chin Chiang; Xiaojie Xu; Yongjian Han; Hang Su; Lingxue Wang; Bo Zhang; Jing Lin; Xiaobing Li; Xiangyang Xie; Tao Wang; Rajeshwar R Tekmal; Tyler J Curiel; Zhi-Min Yuan; Richard Elledge; Yanfen Hu; Qinong Ye; Rong Li
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

Review 7.  The Eya phosphatase: Its unique role in cancer.

Authors:  Hengbo Zhou; Lingdi Zhang; Rebecca L Vartuli; Heide L Ford; Rui Zhao
Journal:  Int J Biochem Cell Biol       Date:  2017-09-05       Impact factor: 5.085

8.  Eya2 promotes cell cycle progression by regulating DNA damage response during vertebrate limb regeneration.

Authors:  Konstantinos Sousounis; Donald M Bryant; Jose Martinez Fernandez; Samuel S Eddy; Stephanie L Tsai; Gregory C Gundberg; Jihee Han; Katharine Courtemanche; Michael Levin; Jessica L Whited
Journal:  Elife       Date:  2020-03-06       Impact factor: 8.140

9.  Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells.

Authors:  Jothi Anantharajan; Hengbo Zhou; Lingdi Zhang; Taylor Hotz; Melanie Y Vincent; Melanie A Blevins; Anna E Jansson; John Wee Liang Kuan; Elizabeth Yihui Ng; Yee Khoon Yeo; Nithya Baburajendran; Grace Lin; Alvin W Hung; Joma Joy; Samarjit Patnaik; Juan Marugan; Pratyaydipta Rudra; Debashis Ghosh; Jeffrey Hill; Thomas H Keller; Rui Zhao; Heide L Ford; CongBao Kang
Journal:  Mol Cancer Ther       Date:  2019-07-08       Impact factor: 6.261

10.  The Eya1 phosphatase promotes Shh signaling during hindbrain development and oncogenesis.

Authors:  Adriana Eisner; Maria F Pazyra-Murphy; Ershela Durresi; Pengcheng Zhou; Xuesong Zhao; Emily C Chadwick; Pin-Xian Xu; R Tyler Hillman; Matthew P Scott; Michael E Greenberg; Rosalind A Segal
Journal:  Dev Cell       Date:  2015-03-26       Impact factor: 12.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.